pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·16h ago·1 min read
save

Johnson & Johnson’s Global Chair of Innovative Medicine Jennifer Taubert Announces Retirement

Aug 7, 2026·read at Endpoints ↗Neutral

Jennifer Taubert, who leads Johnson & Johnson Innovative Medicine worldwide, has said she will step down from her role later this year.

The company indicated that Tom (last name not disclosed) will assume the chairmanship, ensuring continuity for the division’s pipeline and commercial activities.

In a separate move, Takeda announced that its global leader for TYK2 programs is also leaving the firm, highlighting a period of senior‑level turnover in the industry.

Both departures are being watched by investors and partners as they may influence strategic direction and ongoing collaborations.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Jennifer Taubert announces retirement from J&J; Takeda's global TYK2 leader exits”

read at Endpoints ↗
90 words · retrieved 16h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
JOHNSON & JOHNSON3Johnson & Johnson Innovative Medicine2
topics
TYK23

related stories

  • Jun 30These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.BioPharma Dive
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Jun 11Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head testBioPharma Dive
  • Jun 8J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1BBioPharma Dive
  • Jun 8J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS fieldEndpoints